Drug-eluting stents and drug-coated balloons in peripheral interventions

Vascular Disease Management

Volumn 5, Issue 6, 2008, Pages 171-175

  Zeller, Thomas ^a,b   Tepe, Gunnar ^a,b  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; NITINOL; PACLITAXEL; RAPAMYCIN;

BALLOON CATHETER; CLINICAL TRIAL; DRUG COATED BALLOON; DRUG COATING; DRUG ELUTING STENT; DRUG RELEASE; GRAFT PATENCY; HUMAN; KNEE; LIMB ISCHEMIA; LIMB SALVAGE; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; REVIEW; SUPERFICIAL FEMORAL ARTERY; SURGICAL PATIENT;

EID: 67549142452     PISSN: 15538036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Intersociety consensus for the management of peripheral arterial disease. Int Angiol 2007;26:81-157.
2. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation 2000;102:2694-2699.
3. Johnston KW. Femoral and popliteal arteries: Reanalysis of results of balloon angioplasty. Radiology 1992;183:767-771.
4. Johnston KW. Factors that influence the outcome of aortoiliac and femoropopliteal percutaneous transluminal angioplasty. Surg Clin North Am 1992;72:843-850.
5. Duda SH, Poerner TC, Wiesinger B, et al. Drug-eluting stents: Potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 2003;14:291-301.
6. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: A multicenter prospective randomized study. J Vasc Interv Radiol 2001;12:23-31.
7. Grimm J, Muller-Hulsbeck S, Jahnke T, et al. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 2001;12:935-942.
8. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation 2002;106:1505-1509.
9. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-338.
10. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: Long-term results from the SIROCCO Trial. J Endovasc Ther 2006;13:701-710.
11. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-1420.
12. Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: Comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006;240:411-418.
13. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-814.
14. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-1467.
15. Scheller B, Speck U, Schmitt A, et al. Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting. Invest Radiol 2002;37:29-34.
16. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. NEJM 2006;255:2113-2124.
17. Scheller B, Rutsch W, Speck U. Restenosis inhibition by short-term exposure to lipophilic antiproliferative drugs delivered by angiographic contrast media. Safety study. Clinical study report, Parexel International, Berlin, Germany, Study No 1-66797-04; October 2006.
18. Tepe G, Zeller T, Albrecht T, et al. Local Taxane with Short Exposure for Reduction of Restenosis in Distal Arteries: THUNDER Trial. NEJM 2008;358:689-699.
19. Mousa A, Rhee JY, Trocciola SM, et al. Percutaneous endovascular treatment for chronic limb ischemia. Ann Vasc Surg 2005;19:186-191.
20. Trocciola SM, Chaer R, Dayal R, et al. Comparison of results in endovascular interventions for infrainguinal lesions: Claudication versus critical limb ischemia. Am Surg 2005;71:474-479.
21. Feiring AJ, Weolowski AA, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication. Early and one-year outcomes. J Am Coll Cardiol 2004;44:2307-2314.
22. Das T. Optimal therapeutic approaches to femoropopliteal artery intervention. Catheter Cardiovasc Interv 2004;63:21-30.
23. Rand T, Basile A, Cejna M, et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: Pilot study. Cardiovasc Interv Radiol 2006;29:29-38.
24. Bosiers M, Deloose K, Verbist J, Peeters P. Percutaneous transluminal angioplasty for the treatment of below-the-knee critical limb ischemia: Early outcomes following the use of sirolimus-eluting stents. J Cardiovasc Surg (Torino) 2006;47:171-176.
25. Scheinert D, Ulrich M, Scheinert S, et al. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. Eurointervention 2006;2:169-174.
26. Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee lesions: Mid-term results of SiroBTK Study. Cathet Cardiovasc Interv 2006;68:793-798.
27. Siablis D, Kraniotis P, Karnabatidis D, et al. Sirolimus-eluting versus bare metal stents for bailout after suboptimal infrapopliteal angioplasty for chronic limb ischemia: 6 month angiographic results from a nonrandomized prospective single-center study. J Endovasc Ther 2005;12:685-695.
28. Siablis D, Karnabatidis D, Katsanos K, et al. Sirolimus-eluting versus bare stents for after suboptimal infrapopliteal angioplasty for critical limb ischemia: Enduring 1-year angiographic and clinical benefit. J Endovasc Ther 2007;14:241-250.